CDK4 and breast cancer: Since deleting UBR5 sensitizes cells to treatment by Cdk4/6 inhibitors, it is possible that current Cdk4/6 inhibitor–based treatments for breast cancer can be improved by developing novel therapeutics targeting Rb degradation through UBR5, which is frequently amplified in these cancers (Fig. 6I).